Wednesday, January 11, 2012
Immuron Ltd., of Melbourne, Australia, said the FDA cleared its investigational new drug application to begin a Phase IIb trial of bovine colostrum-derived Imm124-E for nonalcoholic steatohepatitis a chronic inflammatory disorder of the liver and fatty liver disease.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.